Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine - United States, March-April 2021.

@article{Shay2021SafetyMO,
  title={Safety Monitoring of the Janssen (Johnson \& Johnson) COVID-19 Vaccine - United States, March-April 2021.},
  author={David K Shay and Julianne M Gee and John R Su and Tanya R. Myers and Paige L. Marquez and Ruiling Liu and Bicheng Zhang and Charles Licata and Thomas A. Clark and Tom T. Shimabukuro},
  journal={MMWR. Morbidity and mortality weekly report},
  year={2021},
  volume={70 18},
  pages={
          680-684
        }
}
On February 27, 2021, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for Janssen (Ad.26.COV2.S) COVID-19 vaccine (Janssen Biotech, Inc., a Janssen Pharmaceutical company, Johnson & Johnson) (1). The Janssen COVID-19 vaccine, the third COVID-19 vaccine authorized for use in the United States, uses a replication-incompetent human adenoviral type 26 vector platform* (2) and is administered as a single intramuscular dose, whereas the first two authorized vaccines… Expand
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021
TLDR
The benefits of CO VID-19 vaccination in preventing COVID-19 morbidity and mortality outweigh the risks for these rare serious adverse events in adults aged ≥18 years; this balance of benefits and risks varied by age and sex. Expand
Evaluation of the safety profile of COVID-19 vaccines: a rapid review
  • Qianhui Wu, M. Dudley, +5 authors Hongjie Yu
  • Medicine
  • BMC Medicine
  • 2021
Background The rapid process of research and development and lack of follow-up time post-vaccination aroused great public concern about the safety profile of COVID-19 vaccine candidates. To provideExpand
US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021.
TLDR
A case series of 12 US patients with CVST and thrombocytopenia following use of the Ad26.COV2.S vaccine is described to inform clinical guidance as Ad 26.COv2.C.S vaccination resumes in the US as well as investigations into the potential relationship between Ad26,COV1.S and heparin exposure. Expand
Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape
TLDR
A snapshot of ongoing vaccine efficacy studies, as well as real-world data on vaccine effectiveness and the impact of virus variants of concern are provided. Expand
A COVID-Positive 52-Year-Old Man Presented With Venous Thromboembolism and Disseminated Intravascular Coagulation Following Johnson & Johnson Vaccination: A Case-Study
TLDR
Findings of elevated D‐dimer levels with decreased fibrinogen and thrombocytopenia with prolonged prothrombin clotting time were consistent for disseminated intravascular coagulation (DIC). Expand
Durability of antibody responses elicited by a single dose of Ad26.COV2.S and substantial increase following late boosting
TLDR
The anamnestic responses after booster immunization imply robust immune memory elicited by single-dose Ad26.COV2.S, which demonstrated protection in a Phase 3 efficacy trial, elicited durable neutralizing and binding antibodies for at least 8 and 6 months, respectively, in adults >18 years of age. Expand
Multisociety statement on coronavirus disease 2019 (COVID-19) vaccination as a condition of employment for healthcare personnel
TLDR
It is recommended that coronavirus disease 2019 (COVID-19) vaccination should be a condition of employment for all healthcare personnel in facilities in the United States and other exemptions as specified by federal or state law are considered. Expand
Laboratory testing for suspected COVID‐19 vaccine–induced (immune) thrombotic thrombocytopenia
  • E. Favaloro
  • Medicine
  • International journal of laboratory hematology
  • 2021
TLDR
The laboratory test processes, as utilised to assess suspected VITT, are reviewed, and there are notable similarities and divergences in testing approaches, potentially leading to identification of slightly disparate patient cohorts. Expand
Temporal association between the COVID-19 Ad26.COV2.S vaccine and acute myocarditis: A case report and literature review
TLDR
A case report of myocarditis following administration of the Janssen vaccine in a healthy, young male is described and a literature review notes a temporal association between COVID-19 vaccination andMyocarditis. Expand
The role of trust in the likelihood of receiving a COVID-19 vaccine: Results from a national survey
TLDR
It is concluded that Hesitancy for COVID-19 vaccines is high overall and among at-risk subgroups, and hesitancy is strongly tied to trust in the vaccine approval and development processes. Expand
...
1
2
...

References

SHOWING 1-9 OF 9 REFERENCES
Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021
TLDR
Patient and provider education about the risk for TTS with the Janssen COVID-19 vaccine, especially among women aged <50 years, as well as the availability of alternative CO VID-19 vaccines, is required to guide vaccine decision-making and ensure early recognition and clinical management of TTS. Expand
US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021.
TLDR
A case series of 12 US patients with CVST and thrombocytopenia following use of the Ad26.COV2.S vaccine is described to inform clinical guidance as Ad 26.COv2.C.S vaccination resumes in the US as well as investigations into the potential relationship between Ad26,COV1.S and heparin exposure. Expand
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
TLDR
A single dose of Ad26.COV2.S protected against symptomatic Covid-19 and asymptomatic SARS-CoV-2 infection and was effective against severe–critical disease, including hospitalization and death, in an international, randomized, double-blind, placebo-controlled, phase 3 trial. Expand
Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS).
TLDR
Fundamental vaccine safety concepts are described, an overview of VAERS is provided for healthcare professionals who provide vaccinations and might want to report or better understand a vaccine adverse event, and how CDC and FDA analyze VAERS data are explained. Expand
Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination
TLDR
It is recommended that treatment with platelet transfusions be avoided because of the risk of progression in thrombotic symptoms and that the administration of a nonheparin anticoagulant agent and intravenous immune globulin be considered for the first occurrence of these symptoms. Expand
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
TLDR
Vaccination with Ch adenoviral vector encoding the spike protein antigen of severe acute respiratory syndrome coronavirus 2 can result in the rare development of immuneThrombotic thrombocytopenia mediated by platelet-activating antibodies against PF4, which clinically mimics autoimmune heparin-induced thromBocy topenia. Expand
Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
TLDR
Findings in five patients who presented with venous thrombosis andThrombocytopenia 7 to 10 days after receiving the first dose of the ChAdOx1 nCoV-19 adenoviral vector vaccine against coronavirus disease 2019 (Covid-19) suggest that they represent a rare vaccine-related variant of spontaneous heparin-induced thromBocytopensia. Expand